Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 26, 2002BloodOpen Access

BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90

View Full Paper
Ask AI
Bookmark
Share

Authors

MGM. GorreCombiMatrixKEKatharine Ellwood‐YenMerck & Co., Inc., Rahway, NJ, USA (United States)GCGabriela ChiosisMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gorre et al. (2002) studied this question.

synapsesocial.com/papers/6a0fa6359e54838161fd00cahttps://doi.org/10.1182/blood-2002-05-1361
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chronic Myeloid Leukemia1999 · 1,638 citations
  2. 2Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation2002 · 241 citations
  3. 3Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.1985 · 272 citations
  4. 4The Biology of Chronic Myeloid Leukemia1999 · 1,317 citations